Literature DB >> 11121174

Childhood-onset schizophrenia/autistic disorder and t(1;7) reciprocal translocation: identification of a BAC contig spanning the translocation breakpoint at 7q21.

W L Yan1, X Y Guan, E D Green, R Nicolson, T K Yap, J Zhang, L K Jacobsen, D M Krasnewich, S Kumra, M C Lenane, P Gochman, P J Damschroder-Williams, L E Esterling, R T Long, B M Martin, E Sidransky, J L Rapoport, E I Ginns.   

Abstract

Childhood-onset schizophrenia (COS) is defined by the development of first psychotic symptoms by age 12. While recruiting patients with COS refractory to conventional treatments for a trial of atypical antipsychotic drugs, we discovered a unique case who has a familial t(1;7)(p22;q21) reciprocal translocation and onset of psychosis at age 9. The patient also has symptoms of autistic disorder, which are usually transient before the first psychotic episode among 40-50% of the childhood schizophrenics but has persisted in him even after the remission of psychosis. Cosegregating with the translocation, among the carriers in the family available for the study, are other significant psychopathologies, including alcohol/drug abuse, severe impulsivity, and paranoid personality and language delay. This case may provide a model for understanding the genetic basis of schizophrenia or autism. Here we report the progress toward characterization of genomic organization across the translocation breakpoint at 7q21. The polymorphic markers, D7S630/D7S492 and D7S2410/D7S646, immediately flanking the breakpoint, may be useful for further confirming the genetic linkage for schizophrenia or autism in this region. Am. J. Med. Genet. (Neuropsychiatr. Genet.) 96:749-753, 2000. Published 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11121174     DOI: 10.1002/1096-8628(20001204)96:6<749::aid-ajmg10>3.0.co;2-k

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  8 in total

1.  Sequencing and analyzing the t(1;7) reciprocal translocation breakpoints associated with a case of childhood-onset schizophrenia/autistic disorder.

Authors:  Jacquelyn R Idol; Anjene M Addington; Robert T Long; Judith L Rapoport; Eric D Green
Journal:  J Autism Dev Disord       Date:  2007-09-19

Review 2.  Group II metabotropic glutamate receptors and schizophrenia.

Authors:  José L Moreno; Stuart C Sealfon; Javier González-Maeso
Journal:  Cell Mol Life Sci       Date:  2009-08-26       Impact factor: 9.261

3.  Presence of large deletions in kindreds with autism.

Authors:  Chang-En Yu; Geraldine Dawson; Jeffrey Munson; Ian D'Souza; Julie Osterling; Annette Estes; Anne-Louise Leutenegger; Pamela Flodman; Moyra Smith; Wendy H Raskind; M Anne Spence; William McMahon; Ellen M Wijsman; Gerard D Schellenberg
Journal:  Am J Hum Genet       Date:  2002-06-07       Impact factor: 11.025

Review 4.  Molecular genetics of autism spectrum disorders.

Authors:  Barkur S Shastry
Journal:  J Hum Genet       Date:  2003-09-11       Impact factor: 3.172

5.  Neurological expression of an inherited translocation of chromosomal 1 and 7.

Authors:  Nabil A AlMajhad; Amal M AlHashem; Inesse A Bouhjar; Brahim M Tabarki
Journal:  Neurosciences (Riyadh)       Date:  2017-01       Impact factor: 0.906

6.  Childhood-Onset Schizophrenia: A Systematic Overview of Its Genetic Heterogeneity From Classical Studies to the Genomic Era.

Authors:  Arnaud Fernandez; Malgorzata Marta Drozd; Susanne Thümmler; Emmanuelle Dor; Maria Capovilla; Florence Askenazy; Barbara Bardoni
Journal:  Front Genet       Date:  2019-12-18       Impact factor: 4.599

Review 7.  Immature dentate gyrus: an endophenotype of neuropsychiatric disorders.

Authors:  Hideo Hagihara; Keizo Takao; Noah M Walton; Mitsuyuki Matsumoto; Tsuyoshi Miyakawa
Journal:  Neural Plast       Date:  2013-06-12       Impact factor: 3.599

Review 8.  Clinical and Neurobiological Relevance of Current Animal Models of Autism Spectrum Disorders.

Authors:  Ki Chan Kim; Edson Luck Gonzales; María T Lázaro; Chang Soon Choi; Geon Ho Bahn; Hee Jeong Yoo; Chan Young Shin
Journal:  Biomol Ther (Seoul)       Date:  2016-05-01       Impact factor: 4.634

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.